by Alex Perry | Jan 5, 2026 | General
Shares of Altimmune, Inc. (NASDAQ:ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide. Altimmune stock is charging ahead with explosive momentum. Why are ALT shares rallying? FDA Grants Breakthrough Therapy Designation...
by Vandana Singh | Jan 5, 2026 | General
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) on Monday shared topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant for CAH and adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome....
by Benzinga Insights | Jan 5, 2026 | General
Axon Enterprise (NASDAQ:AXON) has outperformed the market over the past 5 years by 24.2% on an annualized basis producing an average annual return of 36.74%. Currently, Axon Enterprise has a market capitalization of $47.61 billion. Buying $1000 In AXON: If an investor...
by Benzinga Insights | Jan 5, 2026 | General
In the current session, Aon Inc. (NYSE:AON) is trading at $342.07, after a 0.64% decrease. Over the past month, the stock fell by 0.32%, and in the past year, by 0.96%. With performance like this, long-term shareholders are more likely to start looking into the...
by Chandrima Sanyal | Jan 5, 2026 | General
Oil ETFs directly tied to crude prices slipped on Monday, even as energy equity ETFs surged, underscoring a growing split between oil prices and oil stocks after the U.S. military intervened in Venezuela. Crude-linked funds such as the United States Oil Fund...
Recent Comments